Kimberly J Popovits
CIK 1333482 · Interim CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.37M
Companies
9
Total Filings
150
Lifetime Open-Market Net
-$41.66M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Director | 20,706 | — | — | $0 | 1 | 2026-06-22 |
| TXG | Director | 37,445 | $58.05 | $2.17M | $0 | 8 | 2026-06-08 |
| KNSA | Director | 15,345 | $78.08 | $1.20M | $0 | 10 | 2026-06-02 |
| RYTM | Director | — | $114.32 | — | $0 | 1 | 2026-04-03 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 9,656 | $104.91 | $1.01M | $0 | 3 | 2026-03-23 |
| Talis Biomedical Corp (TLIS) Delisted | Interim CEO | 7,855 | $2.84 | $22.3K | $84.8K | 4 | 2023-06-12 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 2,300 | — | — | $0 | 7 | 2020-06-23 |
| GENOMIC HEALTH INC (GHDX) Delisted | President and CEO | 104,436 | — | — | -$41.74M | 109 | 2019-10-09 |
| ZS Pharma, Inc. (ZSPH) Delisted | Director | — | — | — | $0 | 1 | 2015-06-25 |
Recent Filings · Page 6 of 15
150 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-14 | MyoKardia, Inc. (MYOK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-16 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$209.1K | EDGAR |
| 2018-04-18 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$240.2K | EDGAR |
| 2018-03-16 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | −1,155 | -$74.1K | EDGAR |
| 2018-02-20 | GENOMIC HEALTH INC (GHDX) Delisted | Tax (F) | −6,232 | -$203.5K | EDGAR |
| 2018-02-15 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$157.5K | EDGAR |
| 2018-02-02 | GENOMIC HEALTH INC (GHDX) Delisted | Grant (A) | +23,930 | $0 | EDGAR |
| 2018-01-18 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$178.1K | EDGAR |
| 2017-12-18 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$284.5K | EDGAR |
| 2017-09-18 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$68.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.